View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
Esteban Gonzalez joins the practice in Southfields, Laindon, from Ars Veterinaria in Barcelona, one of the leading veterinary hospitals in Spain.
Esteban (pictured right with VRCC Clinical Director, Henry L’Eplattenier) graduated at the Autonomous University of Barcelona (UAB) in 2002. After working as a veterinary emergency in Paris for a year, he did an 18-month rotating internship of at the UAB. He then worked for three years in a veterinary hospital as a soft tissue and emergency surgeon.
In January 2009, he began a three-year residency in small animal surgery in Neuilly-sur-Seine, France, under the supervision of Dr Jean-Francois Bardet, one of France’s leading veterinary surgeons.
As part of his training, he made several visits to the US with graduates of American surgery, as well as specialists in oncology, anaesthesia and emergency medicine.
During his residency he published several articles and gave presentations at national and international conferences.
Esteban graduated as a European specialist in surgery and a diplomate of the European College of Veterinary Surgeons (ECVS) in February 2014. He then worked as a specialist surgeon in the UK for two years until last year when he joined Ars Veterinaria.
VRCC says his is the first of a number of planned appointments which will result in two veterinary surgeons appointed to each of the practice’s eight specialities.
The business is also undergoing a rebranding and rebuilding operation that will see the practice renamed as Southfields.
Operations manager Daniel Hogan said: "The recruitment plan will ensure we continue to offer state-of-the-art veterinary medicine across the board — in oncology, soft tissue surgery, orthopaedics, internal medicine, feline medicine, anaesthesia, diagnostic imaging, neurology and cardiology."
Clinical director at VRCC Henry L’Eplattenier said: "Esteban is a hugely experienced and well-respected specialist, who we are delighted has chosen to join the team here.
"Having his kind of expertise adds to our already considerable skill-sets and is part of a major drive to attract some of the best people in the industry to VRCC."
For more information, visit www.vrcc.co.uk.
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
The company says more and more CT scanners are being used in general practice, but many teams have been telling them they're not sure if they're using their scanner optimally, or that only some of the team are confident in using it.
The online training aims help teams get the best diagnostic use of CT
The first of the sessions, on 15th June, will cover the indications and benefits of CT in small animal practice.
The second on 22nd June will look at how and when to perform CT reconstructions.
Manuel Pinilla, VetCT Supporting Radiologist and Director of Quality Assurance (pictured right), will be delivering the talks.
Manuel said: “We are seeing a rapid increase in the use of CT in first opinion practice.
"We know CT can provide vital diagnostic information in addition to the more traditional modalities of x-ray and ultrasound.
"However, it can be challenging to optimise the diagnostic capability.
"We’re keen to support veterinary teams to help them get the most out of their machine and do the best for their patients and the owners.”
To register for the training, visit: https://welcome.vet-ct.com/ctcpdwebinars
Written in association with Dr Elinor O’Connor, Senior Lecturer in Occupational Psychology at Alliance Manchester Business School, University of Manchester, the guide is designed for anyone with an interest in the wellbeing of the veterinary team. It provides practical advice to veterinary workplaces on managing stress and promoting wellbeing, alongside examples from the three winning practices of the 2016 MMI/SPVS Wellbeing Awards.
Elinor said: "Addressing stress in veterinary work not only has benefits for the health and wellbeing of each person in the veterinary team, but the business case for reducing work-related stress is clear; stress is associated with poorer performance, increased absenteeism and higher employee turnover. The wellbeing guide provides information about proven techniques for reducing stress at work combined with suggestions for how they might be applied in veterinary workplaces."
Lizzie Lockett, RCVS CEO and Mind Matters Director, said: "Stress at work is an important issue right across the veterinary team. It is sometimes considered just an acceptable part of working in an environment that can be difficult to control, but things can change.
"By making wellbeing a priority practices can support individuals and help their team work better together, and thus provide the best treatment for the animals under their care. This leaflet unpacks some of the root causes of work-related stress and may be of particular interest to practice managers, line managers or health and safety officers."
Good to see that the guide includes a recommendation that practices have measures in place to identify and resolve conflict at work and a clear policy on harassment or bullying, something which research by VetSurgeon.org, VetNurse.co.uk and ex-BSAVA Head of Scientific Policy, Sally Everitt MRCVS found correlated with reduced reports of sustained unpleasant behaviour in practice, a significant source of stress.
The guide can be downloaded here: https://www.vetmindmatters.org/wp-content/uploads/2018/01/MMI-12pp-web.pdf.
It’s very simple.
If you’re a member of VetSurgeon.org, visit the site as soon as possible, and login.
You will then see a red box inviting you to subscribe to a NEW daily or weekly email digest of new questions posted by fellow vets. The box is on the main site home page, and on the community home page.
Subscribe. Today. Now. No time like the present.
Then, whenever you have a question, post it on the site and it will be added to the digest and sent to all subscribed members of the community.
When you get your VetSurgeon Digest, you’ll be presented with a list of the latest questions to skim, both clinical and non-clinical.
Some may catch your eye because you can help, others because you too are interested to know the answer.
Either way, time spent helping others with their questions, or reading answers, counts towards your annual CPD requirement for which you can generate a certificate on the site.
Furthermore, all questions and answers are databased as a searchable knowledge resource for everyone, so whether you’re asking or answering, you’re giving something back to your profession.
So, subscribe now! Did I say that already?
BENEFITS FOR VETERINARY SURGEONS
In short, this offers all the benefits of social media for knowledge-sharing, but with none of the baggage that so often comes with it.
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
Mr Chalkley faced three charges against him. The first was that he failed to identify some or all of the animals tested with Intradermal Comparative Tuberculin (ICT) tests at the farm.
The second charge was that Mr Chalkley had certified that he had carried out ICT tests on 279 animals at the farm and recorded the results on the accompanying paperwork but had, in fact, not adequately identified some or all of the 279 animals and had fabricated the skin thickness measurements recorded for some of them.
In addition, the charge alleged that Mr Chalkley’s conduct was dishonest, misleading and risked undermining government testing procedures designed to promote public health.
The third charge was that between June 2011 and September 2018, Mr Chalkley received payment of approximately £20,000 for ICT tests when, as a result of his conduct in relation to ICT tests at the farm, he was not entitled to such payment.
At the outset of the hearing Mr Chalkley admitted the first charge, that he had not adequately identified some of the animals.
On the third day of the hearing, during his evidence to the Committee, he admitted that his certification of the ICT testing was therefore misleading.
He denied the rest of the charges including that his conduct had been dishonest and that it had risked undermining government testing procedures designed to promote public health.
In considering the charges against Mr Chalkley, the Committee heard that discrepancies regarding the tests that were carried out on the farm in March 2018 were originally raised by the Animal and Plant Health Agency (APHA), on whose behalf Mr Chalkley carried out ICT testing in his capacity as an Official Veterinarian.
When Mr Chalkley gave evidence during the hearing, he explained that he had taken over TB testing for the farm in 2008 and that working conditions on the farm had been difficult throughout the whole period 2008 to 2018. He stated that due to the harsh weather conditions of early 2018, TB testing was difficult, and that the farmer needed to complete the test by March 2018 to avoid a financial penalty.
Mr Chalkley explained that one of the reasons for there being limited time available for him to carry out the test within the time required by the farmer was that he was due to provide veterinary cover at the Cheltenham races the following week and he was unable to find anyone else to cover the tests. Mr Chalkley also explained that during the tests on 5 and 8 March there had been limited farmhands available to assist in processing the cattle through the tests.
In the course of being asked questions by counsel for the RCVS, Mr Chalkley accepted that he had failed to identify some 45% of the animals he had injected on 5 March 2018 and had, in respect of each of the skin thickness measurements for those animals, randomly chosen a figure that he believed would be appropriate based on the breed, age and sex of the animal.
The APHA guidelines state that specific measurements should be made and recorded for each individual animal using callipers. Mr Chalkley said that he could not remember seeing the “pop-up” declaration which appeared when submitting the results to the APHA online and had never read it. He stated that he was not aware that he was making a declaration. However, he accepted that as an Official Veterinarian he was confirming that he had carried out the test properly. While he agreed that he knew that the test contained inaccuracies, he did not accept that he was being dishonest when he submitted the results.
Having considered all the evidence put forward by the RCVS and Mr Chalkley in his own defence, the Committee found that Mr Chalkley had acted dishonestly in deliberately choosing not to take the measurements on 5 March and had instead submitted fabricated alternatives, and so risked undermining public health by failing to carry out his duties as an OV.
The Committee also concluded that Mr Chalkley had been acting dishonestly, as he knew that he was submitting the test results as if they were the authentic outcome of a properly conducted test when in reality, they were no such thing.
The Committee did not accept Mr Chalkley’s evidence that he was unaware of the declaration which accompanied the submission of the test outcome. The Committee therefore found both the first and second charges proved.
In respect of the third charge the Committee found that this was not proven noting that the RCVS had not disproved Mr Chalkley’s explanation regarding his reasons for returning the £20,000 in fees he had received for carrying out TB testing at the farm from the APHA since 2011.
The Committee then considered whether the first two charges, both of which had been found proven, amounted to serious professional misconduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee was prepared to accept that the respondent considered the risk arising from his actions as negligible. Nonetheless, in the Committee’s assessment a real risk existed due to the respondent’s actions and it was precisely the risk which the authorised testing procedure was designed to negate. The simple fact is the respondent could not be sure that each animal he assessed on 8 March 2018 had also been seen by him on 5 March 2018.
“However, the wider point with which the Committee was concerned related to the importance of any member of the profession or public being able to rely absolutely on the integrity of veterinary certification. Those parts of the Code and supporting guidance [concerning certification]… were unequivocal. It was very difficult to conceive of circumstances in which it could ever be justifiable to certify the outcome of a test which had not, in fact, been conducted in a way which was demonstrably valid and reliable. Such conduct was bound to be regarded as disgraceful by members of the profession and the general public.
“Honesty is the bedrock of appropriate certification and the Code and Guidance for the Disciplinary Committee is also unequivocal. Dishonesty in professional practice is always an extremely serious matter and the respondent’s responsibilities in the discharge of his functions as an Official Veterinarian were clear. On this occasion those responsibilities had been compromised.
“For these reasons, the Committee has come to the conclusion that the respondent’s conduct in relation to the facts found proved was disgraceful conduct in a professional respect.”
The Committee then went on to consider the sanction for Mr Chalkley.
The Committee heard oral evidence in mitigation, including from a former colleague who had worked with him in practice since 2006, as well as receiving a large number of written testimonials from various sources that attested to his honesty, integrity, willingness to help others, and charitable work in support of animal welfare.
Mr Chalkley’s counsel, in mitigation, highlighted his long and previously unblemished career, and characterised the conduct as an inexcusable but explicable error of judgement that was entirely isolated and out-of-character. Mr Chalkley’s counsel added that he had not done anything that he thought was seriously wrong, and there was no evidence that any harm had been done and that any risk to public health was not serious.
The Committee accepted that the conduct was isolated and out-of-character and that, furthermore, Mr Chalkley had made early and frank admissions to the APHA and that he had displayed a degree of insight, although the Committee was less confident that he truly understood the seriousness of the potential consequences of his dishonest conduct.
The Committee took into account the aggravating factors, including Mr Chalkley’s breach of trust of his position as an OV, the undermining of the integrity of veterinary certification, dishonesty and the potential public health impacts of his conduct.
Ian Arundale added: “The Committee considered that, having regard to the mitigating features which it had identified, a suspension order would be sufficient to send to the profession and the public a clear signal about the importance to be attached to accurate certification. The Committee considered that in the particular circumstances of this case, a period of three months suspension would be sufficient to achieve this objective.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
Designed to help veterinary teams make clearer, more confident clinical decisions, the flowchart provides a step-by-step approach to diagnosing and managing ear disease in dogs and cats.
Renzo Di Florio, Technical Veterinary Adviser at Krka UK, said: “It takes you through each step, from diagnosis to treatment and long-term management, including identifying cases that might benefit from referral.
"It can also help practices to develop an otitis externa management plan protocol that’s useful for the whole team, and that’s practical and easy to integrate into existing workflows.”
One of the main messages in the flowchart is the central role of cytology in otitis management.
Tim said: “Cytology is essential to assess the level of inflammation and detect the presence of bacteria or Malassezia.
"This helps clinicians make informed decisions about whether antibiotics are truly needed.
"In contrast, culture and sensitivity testing can be misleading when used to guide topical therapy.”
https://www.krka.co.uk/veterinary-knowledge-hub
Speaking at the MSD Animal Health sponsored National Mastitis Panel, David said that more widespread understanding of the issues is urgently required particularly amongst farmers and cattle vets if real progress is to be made.
David said: "There are some notable examples of veterinary practices that have worked with their clients to eliminate the use of CIAs. These are the exceptions, but they illustrate what is possible. As an industry, we need to speed up the rate of change and make a concerted effort to ensure more responsible use of antibiotics becomes the norm, sooner rather than later."
David quoted the British Cattle Veterinary Association (BCVA) position on the responsible use of medicines, which includes the recommendation of minimal use of third and fourth generation cephalosporins, fluoroquinalones and colistin, with these CIAs being limited to use where it has been demonstrated by sensitivity testing that they are the only suitable option to avoid unnecessary suffering.
"There has been agreement on this position amongst the veterinary associations, farmer organisations and milk buyers, but there needs to be more widespread awareness at producer level, particularly within the vet and farmer relationship.
"Farms with a robust herd health plan, where challenges are reduced, will be in the best position to minimise use of CIAs. This takes time and is most effective where there is good cooperation between the farm and its veterinary practice.
"Achieving a significant reduction in the use of CIAs voluntarily will not only minimise the likelihood of disruptive and potentially punitive legislation but will put our cattle industry on the front foot and strengthen its position in global markets."
Fort Dodge has released figures today which point to a continued modest slowdown in the UK veterinary sector, being mitigated by a slight increase in average transaction value (the amount a client spends in a year).
Matthew Rowe, Companion Animal Marketing Manager at Fort Dodge, said: "It's been clear for some time that the veterinary sector is being hit by static growth and an increasingly competitive environment. The reduction in turnover being experienced by many practices is primarily down to current clients visiting less often and fewer new clients being attracted."
Key findings of the Fort Dodge Index for the first quarter of 2009 are:
Alan Robinson said: "In the current climate, the only contributor to turnover growth in many practices seems to be a steady rise in the price of professional fees, consultations and surgery. These have continued to push up average transaction values (by 1.4%) and client values (1.2%) in this first quarter of 2009 despite reducing visit frequency. Drug related income increases seem to be driven by a small increase of POM mark-ups in many practices.
"But this alone will not sustain a successful business and, with transaction volumes still falling, the priority for practices is to maintain client footfall despite increasing competition and falling pet ownership. In today's market, retaining clients is a cheaper and more effective way to maintain client and patient numbers so an emphasis on 'bonding' clients though preventative health care and heath maintenance programmes is key.
"We're seeing a steady increase in the number of practices running these programmes but the percentage of pets involved is still woefully low so the message is that practices can and must do better.
Dermipred is available in two pack sizes – 10mg and 20mg - to treat a range of dog sizes. Both presentations feature a four-way break tablet to enable accurate and flexible dosing, and the product is flavoured to aid compliance. The product is blister-packed for easy dispensing.
Ceva has produced an accompanying electronic brochure on CAD management options. It includes: understanding and decoding CAD, diagnosis and management of the condition.
Allison Henry, Dermipred product manager at Ceva said: "CAD affects approximately a million dogs in the UK, with 70% of all owners believing that the condition has had an impact on their dogs’ quality of life1.
"The addition of Dermipred to Ceva’s extensive dermatology range will provide veterinary professionals with even more treatment options for the management of pruritus and skin inflammation in CAD cases."
To support the launch of Dermipred, Ceva will be running an offer on its dermatology range of products: every client purchasing a box of each Dermipred presentation and a bottle of Modulis will receive one box of Dermipred 10mg, one bottle of the same Modulis size and one bottle of Douxo Calm shampoo and mousse free.
For further information, contact your local Ceva account manager or email cevauk@ceva.com.
Reference
In the literature, Merial stated that Closantel injection (Janssen Animal Health) was effective against flukes aged 9 weeks or older, when in fact, at the time the undated brochure was distributed, Closantel was effective against flukes aged 7 weeks or older.
Merial did not dispute the facts alleged: the company had relied on an out-of-date detailer. The NOAH Code of Practice Committee emphasised the need for members to ensure, when giving comparative data in promotions, that up-to-date data is used. The SPC of any authorised product can be viewed on the VMD's website.
The Committee did commend Merial Animal Health for taking corrective action within two days of notification by the Complainant.
NOAH encourages those interested in finding out more to read the full details of the Committee's rulings on the NOAH website at www.noah.co.uk/code.
The company says the masterclass will equip veterinary surgeons with an understanding of how TPLO fits into the range of treatments for one of the commonest causes of serious hindlimb lameness in the adult dog: cranial cruciate ligament failure.
The course will take place on 13 and 14 September at Improve’s HQ, Alexandra House, Swindon, and will be led by Dr Steve Butterworth, MA VetMB CertVR DSAO MRCVS and RCVS Specialist in Small Animal Surgery (Orthopaedics).
Improve’s Veterinary Operations Manager Juliet Pope MRCVS, said: "We are delighted to offer this new masterclass, created for a maximum of ten delegates to ensure true one-to-one tutoring, and we thank the team at Freelance Surgical for supporting its development.
"The combination of lectures and practical sessions led by Steve Butterworth will revise relevant surgical anatomy to enable delegates to undertake TPLO procedures with confidence. We are particularly pleased to be able to offer radiography as an integral part of the course so that delegates can see the results of their new surgical skills before taking them back to their clinics."
A new equine parasite supplement to the online peer-reviewed publication Parasites and Vectors has been published by Fort Dodge.
Entitled "Equine parasites: diagnosis and control - a current perspective," it contains papers on a range of topics including a major European resistance study into key anthelmintic molecules. It is authored by equine parasitology experts and opinion leaders from around the world and was first published in September 2009. It is freely available at http://www.parasitesandvectors.com/
Virbac Animal Health is launching an initiative to highlight the prevalence of Benign Prostatic Hyperplasia (BPH), a condition suffered by more than 80% of entire male dogs over the age of five1.
The campaign will take place during November - or 'Movember' as it's called by the thousands of men who grow moustaches during the month to raise funds for male prostate and testicular cancer. Virbac says it hopes the campaign will remind dog owners that men are not the only ones to suffer from prostate disorders.
As part of the campaign, the company will be providing participating practices with promotional materials including free dog leads, owner educational and display materials, a press release for local media and practice educational materials.
Chris Geddes MRCVS, Virbac Product Manager, said: "It's estimated that 20% of the country's eight million dogs remain uncastrated throughout their lives. As dogs age, their prostates enlarge, eventually causing symptoms including constipation, lameness and difficulties in urination. However, most of the time clinical signs are absent or vague so diagnosing BPH can be a challenge."
According to Virbac, the traditional rectal examination technique can be an ordeal for both dog and clinician. It's also sometimes inaccurate even in experienced hands and is impossible in very small or large breeds. As a solution, the company has recently introduced Odelis CPSE, the first ELISA test to screen for, diagnose and monitor BPH, available from three UK diagnostic laboratories. The company says it's a cost-effective, precise and reliable alternative to rectal palpation. Virbac also offers Ypozane, a simple tablet treatment for BPH, which takes effect within a week and lasts for six months.
Chris added: "BPH is a serious threat to the health of entire dogs as they get older but owners are often unaware of the potentially serious health problems it can cause if left untreated.
"We hope that, by running our Prostate Awareness Campaign at a time when the media spotlight is already on the dangers of prostate cancer in men, we can help spread the message that owners should also be monitoring older dogs for signs of prostate disease.
"We're providing practices with all the materials they need to promote the campaign in their locality and hope that those getting involved will find it effective in terms of bringing dog-owning clients into the practice for advice on BPH."
For further information on the Prostate Awareness Campaign and to get your free pack please contact your Virbac Territory Manager or contact the company direct on 01359 243243.
Reference1. O'Shea J.D. Studies on the canine prostate gland: Factors influencing its size and weight. J. Comp. Pathol. 1962 72: 321-331.
As a result, clients of LV=GI and Waggel will be able to book an online appointment with a veterinary surgeon within 30 minutes, without having to pay FirstVet's normal £20-30 charge.
Waggel is FirstVet's 26th insurance partner globally, and its third in the UK. The company now has 150 veterinary surgeons working on the platform.
Lucy Broadbridge, LV= GI Pet Product Manager, said: “At LV= GI we’re always looking for ways to help our customers protect what they love, so we’re very excited to be able to work with FirstVet to provide this service to our pet customers. With access to a vet from your smartphone or device, our pet customers will have peace of mind knowing that qualified veterinary advice is on hand 24/7, avoiding unnecessary time, cost and distress of visiting their vet if they don’t really need to."
Under current legislation, there is very little practical assistance that can be offered via an online consultation, other than recommending whether or not the animal needs to be seen by a veterinary surgeon in person. It may also be the case that the online consultation offers little more than a pet owner would get by ringing their normal vet. Nevertheless, online consultations will doubtless grow significantly in 2020, as the players line up to take advantage of any relaxation in the regulations that they hope will allow veterinary surgeons to prescribe medicines for animals they have not seen in person.
Regardless of whether that happens, there is a value in face-to-face communication between a veterinary surgeon or nurse and a client, whether it be for triage or follow up consultations. Independent practices might therefore be well advised to start implementing this kind of technology in practice sooner rather than later, in particular looking at ways that online appointments could be scheduled (perhaps between normal consultations) so as to compete with the short waiting times offered by companies like FirstVet.
Phovia, which was launched in the UK last year, is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp.
Vetoquinol says that when used together they produce light of varying wavelengths that penetrates the skin to different depths, helping to control bacteria and reduce inflammation on the surface of the skin and stimulating regeneration in the epidermal and dermal layers.
The unit is portable, and applications take four minutes once a week.
The authors of the Vetoquinol-funded study say that FLE has already been shown to support and accelerate natural skin healing, but this latest research shows that the benefits go beyond improvement in clinical signs.
The study looked at 35 dogs with a diverse range of skin conditions: 13 had interdigital furunculosis, 10 had deep pyoderma, 6 had wounds, 4 had pyotraumatic dermatitis, and 2 had perianal fistula on presentation.
Eight of 35 dogs were new cases, whereas the remaining 27 were undergoing recrudescence of a prior episode, including pyotraumatic dermatitis, wounds, deep pyoderma, interdigital furunculosis and perianal fistulae.
Thirty dogs (86%) achieved a clinical resolution: 18 with the Fluorescent Light Energy alone and 12 with the concomitant use of FLE and topical antiseptic shampoo.
Five dogs (14%) had a partial response and needed other therapies.
92% percent of owners attested to their pet’s enhanced quality of life, with 74% of dogs displaying at least a 50% improvement in owner-reported behaviour, mood, sleep and playing activities.
The study also reported a 46% reduction in caregiver burden.
Felicity Caddick, Technical Services Manager at Vetoquinol said: “Managing skin conditions often requires the long-term use of shampoos or topical therapies.
"Many owners find this aspect of pet ownership challenging, especially with larger dogs, or less cooperative animals.
"FLE can reduce or in some cases eliminate the need for topical therapies at home, not only simplifying the treatment process but also enhancing convenience and compliance.
"Sharing responsibility for administering ongoing treatment with their vet practice also removes some of the worry associated with their pet’s health.”
Vetoquinol also highlights that Phovia can offer vets a drug-free management option for skin disorders that aligns with the principles of antibiotic stewardship.
Norbrook Laboratories Ltd has launched a new addition to the Loxicom range: Loxicom 0.5mg/ml Oral Suspension for Cats.
Offering alleviation from inflammation and pain, Loxicom Oral Suspension for Cats is billed by Norbrook as 'the new cost-effective treatment for chronic musculo-skeletal disorders in cats that is bio-equivalent to the pioneer.'
The Loxicom range now offers vet practices a choice between 5mg/ml Solution for Injection for Dogs and Cats, 1.5mg/ml Oral Suspension for Dogs and now 0.5mg/ml Oral Suspension for Cats.
Loxicom Oral Suspension for Cats is available in a clear 15ml bottle allowing veterinary surgeons and their clients to monitor product levels and re-order when necessary. The packaging also includes a graduated syringe in 0.5kg increments (from 0.5-10kg) which plugs securely into the bottle allowing accurate, mess-free administration.
Norbrook's small animal range also includes Carprieve, a range of carprofen tablets and injection and Noroclav, the amoxycillin / clavulanic acid range of tablets and injection.
Invicta Animal Health has announced its appointment as exclusive veterinary distributor in the UK for Chloraprep, a licensed human product for cutaneous antisepsis, prior to invasive procedures.
Invicta says Chloraprep is a single use, easy to apply, sterile system, available in a variety of sizes and in clear and tinted versions to enhance the visibility of the area requiring antisepsis, for instance, prior to surgery.
The sterile solution is maintained in a glass ampoule inside a protective outer case and, to prevent contamination, the patented design ensures users don't come into contact with either the contents or the patient's skin.
Rob Watkins, Managing Director of Invicta, said: "Most surgical site infections (SSI's) are the result of contamination from a patient's own skin flora1, a fact which highlights the importance of thorough and effective preparation of the skin as a proactive way to minimise the incidence of SSI's in patients."
According to the company, research has shown that Chloraprep, which contains 2% chlorhexidine and 70% isopropyl alcohol, has demonstrated significantly better antimicrobial activity than other combinations2.
Invicta says the way in which the solution is applied to the skin is as important as the solution itself. Studies show that the most effective way to apply Chloraprep is with a back and forth scrubbing movement because this gives a lower microbial count on the skin than using other application methods3. Once applied, Chloraprep is active in 30 seconds and is effective for up to 48 hours4.
Rob said: "The majority of UK hospitals and the Blood Transfusion Service already use Chloraprep and we are pleased to make this available under the provisions of the cascade."
He added: 'The veterinary nurses I've spoken to love this product, because they're fed up of immersing their dry, cracked hands in disinfectant!'
For further information, please contact Invicta Animal Health on 01403 791313 or email the company at mail@invictavet.com.
References
1. Florman S, Nichols RL. Am J Infect Dis 2007; 3: 51-61.2. Hibbard JS. J Infus Nurs 2005; 28: 194-207.3. Rosenthal K. Nurs Manage 2006; April: 55-66.4. Garcia R et al. Abstracts of the IDSA 40th Annual Meeting 2002; Abs 418.
The complaint related to an advertisement and detailer promoting Felimazole with the wording "Are you taking a heavy-handed approach to hyperthyroidism?" and "with Felimazole, you don't have to!"
The Committee took the view that by implication this referred to Vidalta because Vidalta is the only other licensed oral treatment on the market for hyperthyroidism.
As a result, the Committee found both promotions in breach of Clause 4.3 because of the implication that Vidalta is less safe than Felimazole.
The Committee did not consider the promotions disparaged the manufacturer as there is no evidence to show it is unsafe.
The Committee also found that the table in the detailer (page 4) suggesting that one dosage of 5 mg per day of Felimazole has the same efficacy as two doses of 2.5 mg, (which is contrary to the dosing statement within the SPC: "If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime.") was misleading, contrary to Clause 4.3 of the Code.
Full details of the Committee's rulings are on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortly.
The company has completed a health hazard assessment which concluded that any risk to animal and human health is likely to be low and no greater than expected for this product under normal conditions, as described on the product labelling.
The recall is for the following batches only:
Batch Numbers:
0265-900302-900246-900112-900295-909053-919103-91
Norbrook Laboratories Ltd is contacting veterinary surgeons to examine inventory immediately and quarantine products subject to this recall.
For further information, contact Gary Mckee on +44 2830 264435 or email gary.mckee@norbrook.co.uk
Ms Bucur MRCVS faced three charges against her.
The first charge was that in April 2024, she wrote a prescription for 60 tablets of tramadol 50mg, indicating that it was for the treatment of an animal, when it was intended for the treatment of a human.
The second charge was that she allowed the prescription to be presented at a pharmacy and/or failed to stop that.
The third charge was that her conduct, in relation to the first two charges was dishonest, and misleading, and took place in circumstances where she was not professionally qualified to write a prescription for human use.
At the outset of the hearing, Ms Bucur admitted all the charges and the Committee accepted her admissions.
In relation to charge three, the Committee found that Ms Bucur had been aware that she should not have written the prescription, that she should not have indicated that it was for an animal, that she should not have deleted the prescription for the clinical record on the practice management system, and she should not have allowed or failed to prevent the prescription from being presented for dispensing.
The Committee therefore found all charges proved.
In terms of aggravating factors, the Committee considered that Ms Bucur’s conduct had given rise to a risk of injury because she was not professionally qualified or sufficiently informed to issue a prescription for tramadol, that she had acted recklessly with regard to the potential effects of a controlled, potentially addictive drug and that her conduct had been premeditated.
It also accepted the submission that there was an abuse of Ms Bucur’s professional position as a registered veterinary surgeon, because this had allowed her to issue a prescription.
The Committee also found that Ms Bucur’s conduct was aggravated by her having involved other persons in her misconduct, namely her partner, in an attempt to have the prescription dispensed.
The Committee noted that the charges involved findings of dishonesty, which is regarded at the higher end in terms of the spectrum of gravity of misconduct.
In mitigation, the Committee took into account that the facts proved related to a single incident of the issuing and attempted use of a prescription.
The Committee was of the view that the Ms Bucur’s conduct had failed to promote protection of public health and had breached the legislation around access to controlled drugs.
Even though this was a single incident, the Committee considered that members of the public, if aware of the facts, would be alarmed and concerned at Ms Bucur’s actions.
As a result, the profession could be brought into disrepute and public confidence in the profession undermined.
The Committee therefore found that Ms Bucur’s conduct amounted to serious professional misconduct in a professional respect.
The Committee then considered whether there were any relevant additional personal aggravating or mitigating factors.
The Committee did not find any further aggravating factors; in mitigation it noted that Ms Bucur had no previous complaints of adverse matters in her career.
The Committee accepted that Ms Bucur had made early, open and frank admissions to her conduct.
She had also offered a fulsome and genuine apology and remorse in her witness statement and in the hearing.
The Committee also accepted that she had since worked without further incident and concluded from her witness statement and evidence that she had developed full insight into her misconduct.
She was able to provide a notable number of references and testimonials which were uniform in speaking to her positive qualities as a veterinary surgeon.
The Committee was able to conclude that this has been a very serious but single lapse of judgement, and that there was a relevant context in that Ms Bucur had clearly acted out of concerns to help her father, however misguided.
There were no suggestions of harm, or risk of harm, to animals.
However, the Committee could not ignore that Ms Bucur’s misconduct had occurred in relation to a controlled drug and had contravened important protections designed to protect the public.
Neil Slater, chairing the Committee and speaking on its behalf, said: “The Committee balanced the effect that a suspension would have on Dr Bucur, by depriving her of the ability to practise for a period, with the public interest.
"However, it decided that, in the circumstances, the interests of protecting the public, including the wider public interest, outweighed Dr Bucur’s interests.
“The Committee decided that, in all the circumstances, a suspension was the appropriate and proportionate sanction.
“The Committee considered for how long the suspension should be imposed.
"It considered that the suspension was not required to allow for Dr Bucur to gain any further insight.
"It would purely be required to mark the Committee’s disapproval of Dr Bucur’s misconduct, as a signal to the public and to the profession.
"The Committee concluded that the least period required in all the circumstances is two months.
“The Committee therefore directed to the Registrar that Dr Bucur’s registration be suspended for a period of two months.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Following the outcry from the profession over the disciplinary hearing into Mr M Chikosi, the RCVS' new Operational Board has clarified the the College's position on the use of blankets to move animals.
The hearing found Munhuwepasi Chikosi guilty of unreasonably delaying attending a dog that had been run over at a farm, and of unnecessarily causing her to remain in pain and suffering for at least an hour.
As a result, the Disciplinary Committee directed that Mr Chikosi's name be removed from the Register for serious professional misconduct. The College says that since the appeal window has closed without an appeal being made, Mr Chikosi has now been struck off.
However, the Committee also said: "... his [Mr Chikosi's] advice that Mitzi should be moved on a blanket was wrong, as she may have had an injured back."
This was widely criticised as being out of touch with the practicalities of real life and unsupported by any evidence.
Speaking on behalf of the Board, President Neil Smith said: "We fully support the decision taken by the independent Disciplinary Committee with regard to the Chikosi hearing, with one comment requiring clarification: the issue of whether a blanket can be used to move an injured dog. We consider that it is acceptable, in most cases, to transport an injured dog with the aid of a blanket.
"The profession should be reassured that our Standards Committee [the new name for Advisory Committee] will consider the general issues raised by the Chikosi hearing at its next meeting. This will not be a review of the decision, but form part of the routine consideration of DC hearings made by the Committee to see if they raise issues that require additional guidance and advice."